Garratt is responsible for all activities supporting production of developmental clinical supplies and the manufacture of finished pharmaceutical products including testing, release, stability, and other activities. As a member of the company’s senior management and Pharmaceutical Leadership Team, he will play a key role in shaping corporate strategy and integration of production and related supporting activities with the supply of product necessary to assure we meet our business objectives. He will also be responsible for establishing internal process, analytical and other testing laboratories to assure that we fully understand the manufacturing processes, analytical technologies, and stability technologies and profiles of our products, and that we anticipate and assure our products meet increasing regulatory and quality standards.
Garratt has over twelve years of experience in analytical chemistry, process chemistry and pharmaceutical development at a variety of small, midsize, and large pharmaceutical companies. He was most recently Senior Director of Product Development at AtheroGenics, Inc. where he was responsible for Chemistry, Manufacturing and Control (CMC) activities for active pharmaceutical ingredient and drug product for in-licensing projects including the compilation of CMC sections supporting regulatory filings in the US and overseas. Dr. Ponder joined AtheroGenics in 2003 as Director of Product development. Prior to joining AtheroGenics, Dr. Ponder held positions of increasing responsibility at Endeavor Pharmaceuticals where he was responsible for all CMC activities from API through finished product, and at Solvay Pharmaceuticals, Inc. where he led CMC activities related to support of liquid, solid, semi-solid and encapsulated marketed products.
Dr. Ponder earned his Ph.D. in Pharmaceutical Analysis at the University of Georgia, College of Pharmacy in 1995 and his B.S. in Chemistry in 1989. He is the author of numerous publications, presentations and on review panels of several peer-reviewed journals.